文献速递核素与放射性配体治疗肿瘤 PET/CT甲状腺核医学

镥-177/锕-225标记FAPi二聚体治疗晚期甲状腺髓样癌的长期结局

Long-term outcomes in medullary thyroid cancer patients treated with [177Lu]Lu-DOTAGA.FAPi dimer therapy.
PubMed 文献 · EJNMMI Res · 2026-06-25

这项研究评估了[177Lu]/[225Ac]-DOTAGA.Glu.(FAPi)₂靶向放射性核素治疗在进展期甲状腺髓样癌患者中的疗效、安全性和生存结局。

要点

  • RECIST 1.1评估的部分缓解率为33%,疾病控制率达80%。
  • 中位无进展生存26个月,中位总生存42个月。
  • 仅2例出现3级不良事件,无4级或危及生命毒性。

核心结论

  • [177Lu]/[225Ac]-DOTAGA.Glu.(FAPi)₂治疗在晚期甲状腺髓样癌患者中显示出鼓舞人心的疾病控制、可接受的安全性和初步疗效信号。

主要发现

  • 可评估的17例中,15例按RECIST 1.1评估:部分缓解33%、疾病稳定47%、疾病进展20%,疾病控制率80%。
  • 15例按PERCIST评估:部分缓解47%、疾病稳定40%、疾病进展13%。
  • 14例可评估生化反应,其中64.2%肿瘤标志物稳定或下降,中位降钙素倍增时间为6.7个月。
  • 中位无进展生存26个月,中位总生存42个月;进展组与非进展组总生存差异无统计学意义(log-rank p=0.758)。
  • 未观察到4级或危及生命毒性,仅2例出现3级不良事件(碱性磷酸酶升高和贫血加重各1例)。

关键数值与推荐

  • RECIST 1.1评估的部分缓解率为33%,疾病控制率为80%。
  • PERCIST评估的部分缓解率为47%,疾病稳定率为40%。
  • 中位无进展生存26个月,中位总生存42个月。
  • 中位累积给药活度:镥-177为20.3 GBq,锕-225为6.66 MBq。

临床怎么用

  • 对于进展期甲状腺髓样癌患者,FAP靶向放射性核素治疗可作为候选方案,需结合RECIST和PERCIST及生化标志物综合评估疗效。
  • 治疗期间应监测碱性磷酸酶和血红蛋白等指标,关注3级不良事件。

局限性

  • 中位随访21个月,长期生存数据仍需更长时间验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fibroblast activation protein (FAP)-targeted radionuclide therapy is a promising approach for patients with advanced or metastatic medullary thyroid carcinoma (MTC). This study evaluates efficacy, safety, and survival outcomes of [177Lu]/[225Ac]-DOTAGA.Glu.(FAPi)₂ therapy in this population. RESULTS: Nineteen patients with progressive MTC were treated with either [¹⁷⁷Lu]Lu-DOTAGA.Glu.(FAPi)₂ or [²²⁵Ac]Ac-DOTAGA.Glu.(FAPi)₂, receiving a median of 5 cycles. The median cumulative activity administered was 20.3 GBq (Lu) and 6.66 MBq (Ac) and the median follow-up was 21 months. Of the 17 evaluable patients, radiological response was assessed in 15 patients using the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). The analysis demonstrated a partial response (PR) in 33% of patients, stable disease (SD) in 47%, and progressive disease (PD) in 20%, resulting in a disease control rate (DCR) of 80%. Positron emission tomography response criteria in solid tumors (PERCIST) evaluation (n = 15) showed 47% PR, 40% SD, and 13% PD. Biochemical response was evaluable in 14 patients: 64.2% showed stable or decreasing tumor markers. Median calcitonin doubling time was 6.7 months. Clinical progression occurred in 2 patients. Median PFS was 26 months; median OS was 42 months. No statistically significant difference in OS was observed between progression and non-progression groups (log-rank p-0.758). No Grade 4 or life-threatening toxicities were observed. Only two patients experienced Grade 3 adverse events-one with elevated alkaline phosphatase and one with worsening anemia. All other hematologic and biochemical toxicities were limited to Grade 1-2. CONCLUSION: [177Lu]/[225Ac]-DOTAGA.Glu.(FAPi)₂ therapy shows encouraging disease control, acceptable safety, and preliminary efficacy signals such as increased survival in the treated patients of advanced MTC.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Ballal S, Priyanka GB, Yadav MP, et al. Long-term outcomes in medullary thyroid cancer patients treated with [177Lu]Lu-DOTAGA.FAPi dimer therapy. EJNMMI Res. 2026. PMID: 42348144. doi:10.1186/s13550-026-01474-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。